- View All
Dr. Miller's point is well-taken. It is because there has been a lack of existing data about differential efficacy among NSAIDs that we took the approach of grouping them into classes, since it is a common clinical question as to whether one class of NSAID is better than another for gout flares in particular(2-5). We did this to better understand whether there were any specific class differences since this sort of study has never been done specifically in gout flares.
has subject area